Matches in Wikidata for { <http://www.wikidata.org/entity/Q49662502> ?p ?o ?g. }
- Q49662502 description "2018 nî lūn-bûn" @default.
- Q49662502 description "2018年の論文" @default.
- Q49662502 description "2018年学术文章" @default.
- Q49662502 description "2018年学术文章" @default.
- Q49662502 description "2018年学术文章" @default.
- Q49662502 description "2018年学术文章" @default.
- Q49662502 description "2018年学术文章" @default.
- Q49662502 description "2018年学术文章" @default.
- Q49662502 description "2018年學術文章" @default.
- Q49662502 description "2018年學術文章" @default.
- Q49662502 description "2018年學術文章" @default.
- Q49662502 description "2018年學術文章" @default.
- Q49662502 description "2018年學術文章" @default.
- Q49662502 description "2018년 논문" @default.
- Q49662502 description "article científic" @default.
- Q49662502 description "article scientific" @default.
- Q49662502 description "article scientifique" @default.
- Q49662502 description "articol științific" @default.
- Q49662502 description "articolo scientifico" @default.
- Q49662502 description "artigo científico" @default.
- Q49662502 description "artigo científico" @default.
- Q49662502 description "artigo científico" @default.
- Q49662502 description "artikel ilmiah" @default.
- Q49662502 description "artikull shkencor" @default.
- Q49662502 description "artikulong pang-agham" @default.
- Q49662502 description "artykuł naukowy" @default.
- Q49662502 description "artículo científico publicado en 2018" @default.
- Q49662502 description "artículu científicu" @default.
- Q49662502 description "bilimsel makale" @default.
- Q49662502 description "bài báo khoa học" @default.
- Q49662502 description "naučni članak" @default.
- Q49662502 description "scienca artikolo" @default.
- Q49662502 description "scientific article published on 26 January 2018" @default.
- Q49662502 description "scientific article published on 26 January 2018" @default.
- Q49662502 description "scientific article published on 26 January 2018" @default.
- Q49662502 description "teaduslik artikkel" @default.
- Q49662502 description "tieteellinen artikkeli" @default.
- Q49662502 description "tudományos cikk" @default.
- Q49662502 description "vedecký článok" @default.
- Q49662502 description "vetenskaplig artikel" @default.
- Q49662502 description "videnskabelig artikel" @default.
- Q49662502 description "vitenskapelig artikkel" @default.
- Q49662502 description "vitskapeleg artikkel" @default.
- Q49662502 description "vědecký článek" @default.
- Q49662502 description "wetenschappelijk artikel" @default.
- Q49662502 description "wissenschaftlicher Artikel" @default.
- Q49662502 description "επιστημονικό άρθρο" @default.
- Q49662502 description "мақолаи илмӣ" @default.
- Q49662502 description "наукова стаття, опублікована в січні 2018" @default.
- Q49662502 description "научна статия" @default.
- Q49662502 description "научная статья" @default.
- Q49662502 description "научни чланак" @default.
- Q49662502 description "научни чланак" @default.
- Q49662502 description "מאמר מדעי" @default.
- Q49662502 description "مقالة علمية نشرت في 26 يناير 2018" @default.
- Q49662502 description "২৬ জানুয়ারি ২০১৮-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ" @default.
- Q49662502 description "บทความทางวิทยาศาสตร์" @default.
- Q49662502 description "სამეცნიერო სტატია" @default.
- Q49662502 name "Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive" @default.
- Q49662502 name "Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive" @default.
- Q49662502 type Item @default.
- Q49662502 label "Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive" @default.
- Q49662502 label "Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive" @default.
- Q49662502 prefLabel "Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive" @default.
- Q49662502 prefLabel "Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive" @default.
- Q49662502 P1433 Q49662502-78B443ED-0603-4884-BEB8-9276DC8514BC @default.
- Q49662502 P1476 Q49662502-8991D9EB-7DE2-4B83-9115-4FFDB9FF53A8 @default.
- Q49662502 P2093 Q49662502-1505C50A-3F16-4169-B7ED-6EDB84F241B4 @default.
- Q49662502 P2093 Q49662502-169C2A8B-999B-4729-8301-6D2ED19C7B05 @default.
- Q49662502 P2093 Q49662502-2A759D1D-83C7-49EF-9FBC-7CF524F18850 @default.
- Q49662502 P2093 Q49662502-45B3901D-8D1B-43E4-9DD3-68C3B19E6092 @default.
- Q49662502 P2093 Q49662502-5710D55A-615C-4FC7-95DC-5AC72612EDDB @default.
- Q49662502 P2093 Q49662502-5F971717-3E8B-45F3-832B-EE21C83EC6B8 @default.
- Q49662502 P2093 Q49662502-6D6234AB-AC2A-48B3-819E-EB7B33D845BD @default.
- Q49662502 P2093 Q49662502-805632A9-9548-4144-BCF5-429FF19AD2C2 @default.
- Q49662502 P2093 Q49662502-81B67B99-4C71-439E-A49C-1466E5A82522 @default.
- Q49662502 P2093 Q49662502-93BC5B66-2CB3-4D61-86A6-31EE9B92142B @default.
- Q49662502 P2093 Q49662502-CEA3B668-A8DA-4458-8E78-401B0B2A5C2C @default.
- Q49662502 P2093 Q49662502-F7ABBE23-CBE9-4DB9-8C77-64482AA05872 @default.
- Q49662502 P2093 Q49662502-FD693B81-FBE9-487F-B9AC-5A43B3404846 @default.
- Q49662502 P304 Q49662502-53DF1879-E2A5-4329-90F6-C7844F7CCEF1 @default.
- Q49662502 P31 Q49662502-F318154C-17DA-4D04-B8CF-A1AAC166C84F @default.
- Q49662502 P356 Q49662502-060056FB-00EF-4D07-B53A-3B919FA50C17 @default.
- Q49662502 P407 Q49662502-CE0DD90A-5600-4525-8F95-A0DEA8153AB5 @default.
- Q49662502 P433 Q49662502-9BD8A5E6-00C1-4616-AF2B-918196AF5229 @default.
- Q49662502 P478 Q49662502-F5ABAA23-EEED-4974-876D-E464983B788C @default.
- Q49662502 P50 Q49662502-26333FE6-063E-4905-A601-98CB17F6799B @default.
- Q49662502 P50 Q49662502-46C2977F-EC5C-4566-ABE2-65733C6120DA @default.
- Q49662502 P50 Q49662502-4E24588A-0987-45EE-A14D-0A345D98C1AE @default.
- Q49662502 P50 Q49662502-AF8B08D9-43C6-413E-9C14-B4F1050935CC @default.
- Q49662502 P577 Q49662502-E47579E3-112B-4EBF-B9C2-D07CF8389950 @default.
- Q49662502 P698 Q49662502-1897E526-E2BF-4766-ACA1-BEC7CB453348 @default.
- Q49662502 P921 Q49662502-F4C5C272-158E-477A-A4DE-883CE795C408 @default.
- Q49662502 P356 JCO.2017.74.0126 @default.
- Q49662502 P698 29373094 @default.
- Q49662502 P1433 Q400292 @default.
- Q49662502 P1476 "Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer" @default.
- Q49662502 P2093 "Ekaterina Trishkina" @default.
- Q49662502 P2093 "Igor Bondarenko" @default.
- Q49662502 P2093 "Jaeyun Lim" @default.